The administered mixture and measured organism were different
A 2025 trial randomized 38 adults with functional bowel disorders to an eight-strain probiotic mixture or placebo for eight weeks. The listed mixture included named lactobacilli, bifidobacteria and Streptococcus thermophilus, but not Faecalibacterium prausnitzii. [1]
The investigators nevertheless reported increased relative abundance of F. prausnitzii in stool sequencing after supplementation. This was a downstream microbiome observation, not proof that the capsule delivered that organism. [1]
Neither a stool finding nor a title establishes retail composition
Only 29 participants completed the trial and entered its per-protocol analysis. Some authors were employees of ILDONG Bioscience. The small, mixed-intervention study cannot isolate the role of F. prausnitzii in any symptom change. [1]
To assess a product said to contain this organism, inspect its actual strain declaration and evidence about that preparation. This study does not establish current retail availability, product viability or clinical effectiveness for a different formulation. [1]
Read the methods before the marketing claim
Imagine an article says a supplement increased bacterium X. It does not follow that X was one of the organisms in the supplement; the methods must identify what participants received.
| Detail | Interpretation |
|---|---|
| Capsule strains | What was administered |
| Stool relative abundance | What was measured afterward |
| Retail claim | Needs its own verification |
Sources for this article
- Therapeutic Modulation of the Gut Microbiome by Supplementation with Probiotics (SCI Microbiome Mix) in Adults with Functional Bowel Disorders: A Randomized, Double-Blind, Placebo-Controlled Trial - PMC
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.